Alexander Burik, Author at Labiotech.eu

About

Born in Chicago, I grew up close to Frankfurt, Germany. I hold an MSc in Neuroscience from University College London and a BA in Biochemistry from Knox College in the US.
Outside of science-related activities, I enjoy skiing and writing music.

Articles by Alexander Burik

News and Trends 5 Jun 2018

French Biotech Raises €40M to Fight Hepatitis B and NASH

Enyo Pharma has completed a Series B financing round to start Phase II trials by the end of this year testing its lead compound in two different forms of liver disease. Enyo Pharma, based in Lyon, has raised €40M from OrbiMed and other investors to start two Phase II trials testing its lead drug candidate […]

June 5, 2018 - 2 minutesmins - By Alexander Burik

News and Trends 4 Jun 2018

British Company Gets a $100M Boost to Develop a Surgical Robotic Arm

CMR Surgical has raised an impressive Series B round to develop a robotic arm to help during surgery that mirrors the movement of a human arm. CMR Surgical, based in Cambridge, UK, has raised $100M (€85M) in Series B funding to bring its surgical robot technology closer to a market launch in Europe and the US. […]

June 4, 2018 - 2 minutesmins - By Alexander Burik

News and Trends 1 Jun 2018

FDA Puts Clinical Trial for CRISPR Therapy on Hold

The FDA has put a hold on CRISPR Therapeutics’ planned Phase I/II trial testing a CRISPR gene-editing therapy in patients with sickle cell disease, which will likely delay the use of CRISPR-based therapies in humans. CRISPR Therapeutics, headquartered in Basel, Switzerland, and its partner Vertex Pharmaceuticals will have to postpone their plans to start a Phase I/II trial […]

June 1, 2018 - 2 minutesmins - By Alexander Burik

Startup Scout 1 Jun 2018

This Dutch Biotech Gets Inspiration From Snake Venom to Restore Blood Clotting

This week we’re in Leiden, the Netherlands, visiting VarmX. The biotech develops therapeutic proteins based on a peptide found in snake venom to restore blood clotting in patients with acute bleeding. Mission: Founded in 2016 as a spin-out from the University of Leiden, VarmX aims to restore blood clotting in patients with acute, internal bleeding after taking […]

June 1, 2018 - 2 minutesmins - By Alexander Burik

Grapevine Fungus Nanoparticle Technology

More News! 31 May 2018

A Trojan Horse of Nanoparticles Could Fight Fungal Infections in Grapevines

German researchers have developed nanoparticles that can protect grapevines from a fungal disease that causes great financial damage to winegrowers each year. A research team at the University of Mainz, led by Frederik Wurm, has developed a nanotechnology that can protect and heal grapevines from infestation by the fungal disease Esca. The technology is made of […]

May 31, 2018 - 2 minutesmins - By Alexander Burik

News and Trends 31 May 2018

UK Biotech Wins Major Grant to Manage Chronic Pain With Antibodies

Innovate UK has awarded a grant to Iontas to develop antibodies that block pain transmission by nerve cells in patients with chronic pain. Iontas, based in Cambridge, has been awarded a grant of £556K (€633K) from Innovate UK to develop its antibody platform, KnotBody, for therapeutic applications in chronic pain management. Iontas’ antibody approach could provide […]

May 31, 2018 - 2 minutesmins - By Alexander Burik

News and Trends 28 May 2018

Genmab and Janssen Suffer Combination Therapy Setback

Janssen will discontinue a Phase I study testing Danish biotech Genmab’s blood cancer blockbuster daratumumab combined with a candidate checkpoint inhibitor in patients with multiple myeloma. Janssen, which obtained the exclusive global rights to commercialize daratumumab from Genmab in 2012, will also discontinue a Phase Ib/II study of daratumumab in patients with non-small cell lung […]

May 28, 2018 - 2 minutesmins - By Alexander Burik

News and Trends 25 May 2018

Norwegian Pancreatic Cancer Vaccine Drastically Improves Survival

Targovax has obtained positive Phase I/II results showing its pancreatic cancer vaccine improved the survival of 32 patients also receiving chemotherapy over two years. Targovax, based in Oslo, Norway, has obtained positive Phase I/II results confirming the efficacy of its pancreatic cancer vaccine in a larger patient population and over a longer time period than […]

May 25, 2018 - 3 minutesmins - By Alexander Burik

News and Trends 24 May 2018

Organs-on-a-Chip for Drug Research in a Range of Diseases Make it to the Market

CN Bio Innovations has globally launched an organ-on-a-chip device that allows scientists to test potential drugs on living human organ models. CN Bio Innovations, an Oxford University spin-out, has launched a device that enables scientists to test potential drugs in conventional cell culture labs without the need for animal models. The technology, which has been […]

May 24, 2018 - 2 minutesmins - By Alexander Burik

More News! 23 May 2018

Danish Biotech Raises Series A Round to Advance Microbe Engineering Technology

Biosyntia has raised €4M in Series A financing from Sofinnova Partners to bring its microbe engineering technology closer to commercialization. Biosyntia, based in Copenhagen, has raised €4M in Series A financing to continue developing its biosynthetic selection technology to produce complex compounds by fermentation. The funding was provided by Sofinnova Partners, a new investor and leading European […]

May 23, 2018 - 2 minutesmins - By Alexander Burik

Nabriva Therapeutics Pneumonia Antibiotic

News and Trends 23 May 2018

Another Pneumonia Antibiotic is Close to Treating Patients

Nabriva Therapeutics has obtained positive Phase III results for its antibiotic lefamulin and plans to seek FDA approval for the drug by the end of this year. Nabriva Therapeutics has obtained a second round of positive Phase III results for lefamulin, its antibiotic targeting community-acquired pneumonia. The drug was shown to be as effective as […]

May 23, 2018 - 2 minutesmins - By Alexander Burik

News and Trends 23 May 2018

Grass Pollen Allergy Vaccine Gets Encouraging Phase II Results

Allergy Therapeutics has obtained positive Phase II results for its grass pollen allergy vaccine and plans to launch a Phase III study next year. British biotech Allergy Therapeutics has obtained positive Phase II results for its grass pollen allergy vaccine. Roughly 30% of the population in Europe are allergic to grass pollen. The company plans […]

May 23, 2018 - 2 minutesmins - By Alexander Burik

Knowledge hub

Categories

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

Approaches

Therapeutic areas

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Alexander Burik

About

Articles by Alexander Burik

French Biotech Raises €40M to Fight Hepatitis B and NASH

British Company Gets a $100M Boost to Develop a Surgical Robotic Arm

FDA Puts Clinical Trial for CRISPR Therapy on Hold

This Dutch Biotech Gets Inspiration From Snake Venom to Restore Blood Clotting

A Trojan Horse of Nanoparticles Could Fight Fungal Infections in Grapevines

UK Biotech Wins Major Grant to Manage Chronic Pain With Antibodies

Genmab and Janssen Suffer Combination Therapy Setback

Norwegian Pancreatic Cancer Vaccine Drastically Improves Survival

Organs-on-a-Chip for Drug Research in a Range of Diseases Make it to the Market

Danish Biotech Raises Series A Round to Advance Microbe Engineering Technology

Another Pneumonia Antibiotic is Close to Treating Patients

Grass Pollen Allergy Vaccine Gets Encouraging Phase II Results

Subscribe to our newsletter to get the latest biotech news!

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

About

Articles by Alexander Burik

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!